Atossa Genetics receives positive safety committee assessment of first cohort
Atossa announced it has received a positive interim safety assessment of the first cohort receiving proprietary oral Endoxifen in its Phase 1 dose escalation study. Endoxifen is an active metabolite of the FDA approved drug tamoxifen which is indicated for breast cancer and breast cancer prevention. June 26, 2017